Concluding remarks

Journal of Alzheimer's Disease

Volumn 20, Issue SUPPL.1, 2010, Pages

  Mendonça, Alexandre ^a   Cunha, Rodrigo A ^b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; BRAIN PROTECTION; COFFEE; COGNITION; DEMENTIA; DIETARY INTAKE; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; CLINICAL TRIAL; METHODOLOGY;

ALZHEIMER DISEASE; CAFFEINE; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 77956261341     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-01411     Document Type: Editorial

References (32)

1. Ritchie K, Artero S, Portet F, Brickman A, Muraskin J, Beanino E, Ancelin M-L, Carriere I (2010) Caffeine, cognitive functioning and white matter lesions in the elderly: establishing causality from epidemiological evidence. J Alzheimers Dis 20(Supplement), 161-166.
2. Eskelinen MH, Kivipelto M (2010) Caffeine as a protective factor in dementia and Alzheimers disease. J Alzheimers Dis 20(Supplement), 167-174.
3. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N (2010) Caffeine intake and dementia: systematic review and metaanalysis. J Alzheimers Dis 20(Supplement), 187-204.
4. Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A, (2010) Caffeine exposure and the risk of Parkinsons disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 20(Supplement), 221-238.
5. Prediger RDS (2010) Effects of caffeine in Parkinsons disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 20(Supplement), 205-220.
6. Kyle J, Fox HC, Whalley LJ (2010) Caffeine, cognition, and socioeconomic status. J Alzheimers Dis 20(Supplement), 151-159.
7. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH,Wekstein DR, Markesbery WR (1996) Linguistic ability in early life and cognitive function and Alzheimers disease in late life. Findings from the Nun Study. JAMA 275, 528-532.
8. Arendash GW, Cao C (2010) Caffeine and coffee as therapeutics against Alzheimers disease. J Alzheimers Dis 20(Supplement), 117-126.
9. Cunha RA, Agostinho PM (2010) Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis 20(Supplement), 95-116.
10. Prediger RD, Batista LC, Takahashi RN (2005) Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol Aging 26, 957-964.
11. Green RC, DeKosky ST (2006) Primary prevention trials in Alzheimer disease. Neurology 67 (9 Suppl 3), S2-5.
12. Pelligrino DA, Xu H-L, Vetri F (2010) Caffeine and the control of cerebral hemodynamics. J Alzheimers Dis 20(Supplement), 51-62.
13. Chen X, Ghribi O, Geiger JD (2010) Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimers and Parkinsons diseases. J Alzheimers Dis 20(Supplement), 127-141.
14. Biessels GJ (2010) Caffeine, diabetes, cognition, and dementia. J Alzheimers Dis 20(Supplement), 143-150.
15. Chen J-F, Yu L, Shen H-Y, He J-C, Wang X, Zheng R (2010) What knock-out animals tell us about the effects of caffeine. J Alzheimers Dis 20(Supplement), 17-24.
16. Ribeiro JA, Sebastião AM (2010) Caffeine and adenosine. J Alzheimer Dis 20(Supplement), 3-15.
17. Vellas B, Andrieu S, Sampaio C, Wilcock G; European Task Force group (2007) Disease-modifying trials in Alzheimers disease: a European task force consensus. Lancet Neurol 6, 56-62.
18. Santos C, Lunet N, Azevedo A, de Mendonca A, Ritchie K, Barros H (2010) Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal. J Alzheimers Dis 20(Supplement) 175-185.
19. Alsene K, Deckert J, Sand P, de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28, 1694-1702.
20. Cornelis MC, El-Sohemy A, Campos H (2007) Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 86, 240-244.
21. Ŕetey JV, Adam M, Khatami R, Luhmann UF, Jung HH, Berger W, Landolt HP (2007) A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 81, 692-698.
22. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA (2006) Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsons disease. J Neurosci 26, 535-541.
23. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G, European Task Force Group (2008) Endpoints for trials in Alzheimers disease: a European task force consensus. Lancet Neurol 7, 436-450.
24. de Carvalho M, Marcelino E, de Mendonca A (2010) Electrophysiological studies in healthy subjects involving caffeine. J Alzheimers Dis 20(Supplement), 63-69.
25. Koppelstaetter F, Poeppel TD, Siedentopf CM, Ischebeck A, Kolbitsch C, Mottaghy FM, Felber SR, Jaschke WR, Krause BJ (2010) Caffeine and cognition in functional magnetic resonance imaging. J Alzheimers Dis 20(Supplement), 71-84.
26. Yu L, Shen HY, Coelho JE, Aráujo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, Müller CE, Linden J, Cunha RA, Chen JF (2008) Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63, 338-346.
27. Costenla AR, Cunha RA, de Mendonca A (2010) Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers Dis 20(Supplement), 25-34.
28. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimers Disease Neuroimaging Initiative (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 132 (Pt 5), 1355-1365.
29. Lara DR (2010) Caffeine, mental health, and psychiatric disorders. J Alzheimers Dis 20(Supplement), 239-248.
30. Smith AP (2009) Caffeine, cognitive failures and health in a non-working community sample. Hum Psychopharmacol 24, 29-34.
31. Nehlig A (2010) Is caffeine a cognitive enhancer? J Alzheimers Dis 20(Supplement), 85-94.
32. Ferŕe S (2010) Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis 20(Supplement), 35-49.